ABT
ABBOTT LABORATORIES
NYSE · Healthcare · Medical - Devices · US
$115.46
+5.54%Nov 4, 2026, 07:18 UTC
ABBOTT LABORATORIES Medical Japan launched a catheter-based treatment device for atrial fibrillation that enables procedures without general anesthesia.
Source:Nov 3, 2026, 12:30 UTC
BridgeBio announced that two moderated posters and three posters on acoramidis and ATTR-CM, plus a BridgeBio-supported poster led by ABBOTT LABORATORIES, are scheduled for presentation at the American Heart Association, Inc. Scientific Sessions 2026.
Source:Nov 2, 2026, 14:00 UTC
ABBOTT LABORATORIES announced one-year ABBOTT LABORATORIES results for its investigational Amulet 360 left atrial appendage occluder, reporting high closure rates and a low incidence of stroke among people with non-valvular atrial fibrillation.
Source:Nov 1, 2026, 20:45 UTC
ABBOTT LABORATORIES announced strong 30-day results from its TECTONIC study evaluating the investigational SonicForce Coronary IVL System.
Source:Oct 29, 2026, 13:00 UTC
ABBOTT LABORATORIES announced that it initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea Mitral Valve System for symptomatic mitral valve disease patients who are not candidates for surgery or transcatheter repair.
Source:Oct 26, 2026, 13:00 UTC
ABBOTT LABORATORIES launched its next-generation Oncodetect whole-genome sequencing test for detecting molecular residual disease in cancer patients during and after treatment.
Source:Oct 23, 2026, 13:15 UTC
ABBOTT LABORATORIES presented ABBOTT LABORATORIES data from the Beta-CORRECT study showing that its Oncodetect whole-genome sequencing test had a 30-percentage-point absolute improvement in sensitivity and that patients with molecular residual disease had a 10.6-fold higher risk of recurrence.
Source:Oct 22, 2026, 20:54 UTC
Catheter Precision, Inc. announced publication of the first comparative study evaluating its LockeT suture retention device against ABBOTT LABORATORIES's Perclose device after large-bore venous access.
Source:Oct 22, 2026, 15:02 UTC
Abbott said it plans to spin off its Nutrition business, valued at $8.5 billion, by 2027.
Source:Oct 21, 2026, 14:31 UTC
ABBOTT LABORATORIES shares fell following its third-quarter earnings miss and lower 2026 sales guidance.
Source:Oct 21, 2026, 13:45 UTC
ABBOTT LABORATORIES reported quarterly earnings of $1.42 per share, below the Zacks Consensus Estimate of $1.43 and up from $1.30 per share a year earlier.
Source:Oct 21, 2026, 11:30 UTC
ABBOTT LABORATORIES reported third-quarter 2026 sales growth of 14.5% and comparable sales growth of 7.0%, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42.
Oct 21, 2026, 11:28 UTC
ABBOTT LABORATORIES said Daniel Salvadori will become chief executive of its new nutrition company.
Source:Oct 21, 2026, 11:25 UTC
Abbott announced plans to spin off its global nutrition business.
Oct 7, 2026, 13:00 UTC
ABBOTT LABORATORIES introduced Ensure Max Protein 3-in-1 Muscle Support, a powder with 30 grams of protein, 5 grams of creatine monohydrate and 3 grams of calcium HMB per serving, available in chocolate and vanilla at major U.S. retailers.
Source:Oct 6, 2026, 08:45 UTC
Lazada held its annual LazMall Brand Gala 2026, honoring Abbott, Estée Lauder Companies and Samsung as LazMall Brand of the Year among winners across 10 award categories.
Source:Oct 5, 2026, 23:59 UTC
FCM Travel Asia expanded its Japan management team, appointing Benjamin Beh as General Manager of FCM Travel Japan, Aki Yonezu as Head of Account Management and Meetings & Events, Norimasa Arase as Sales & Marketing Manager, and Joe Nakazawa as Director of Supplier Relations and Strategic Partnerships at Flight Centre Travel Group in Japan.
Source:Oct 5, 2026, 13:00 UTC
Abbott received U.S. FDA approval for updates to its CardioMEMS HF System enabling new patient-facing capabilities through the CardioGuide HF App.
Source:Sep 30, 2026, 23:45 UTC
Abbott Laboratories agreed to pay $348.7 million to the United States and $35.5 million to 39 states to settle allegations that it sold contaminated infant formula and nutritional products to government health programs, with Mississippi receiving over $770,000 in restitution.
Source:Sep 24, 2026, 15:45 UTC
Andhra Pradesh IT & HRD Minister Nara Lokesh appealed to Abbott India MD Ishteyaque Amjad to set up a medical devices/diagnostics manufacturing unit in an AP MedTech Zone or electronics manufacturing cluster, a generic drug unit at the Nakkapalli bulk drug park, and an Abbott GCC in Visakhapatnam.
Source:Sep 23, 2026, 11:30 UTC
An FDA advisory committee met to vote on whether the agency should approve Grail's Galleri multi-cancer blood test.
Sep 23, 2026, 10:00 UTC
Pakistan's Finance Minister Muhammad Aurangzeb met with an Abbott representative in New York to discuss accelerating Pakistan's Hepatitis C eradication programme, pharmaceutical regulation and exports, and Abbott's cancer treatment projects in Pakistan.
Source:Sep 21, 2026, 23:59 UTC
Abbott Laboratories agreed to a $384 million settlement with North Carolina and 39 other states plus the federal government over allegations involving contaminated infant formula tied to the 2022 nationwide baby formula shortage.
Source:Sep 21, 2026, 23:59 UTC
The Community Blood Center reported a critical Type O blood shortage after Brown County hospitals requested at least 24 emergency units for six patients, with several blood types at only a two-to-three-day supply.
Source:Sep 18, 2026, 09:57 UTC
Abbott announced that its FreeStyle Libre 2 received integrated continuous glucose monitoring (iCGM) approval from China's National Medical Products Administration, making it the first and currently only dynamic glucose monitor in China approved to assist adult diabetes treatment decisions.
Source:Sep 17, 2026, 16:43 UTC
Abbott's board of directors declared a quarterly common dividend of 63 cents per share, its 411th consecutive quarterly dividend.
Source:Sep 14, 2026, 18:02 UTC
Abbott Laboratories agreed to pay about $385 million to the U.S. Department of Justice to settle allegations over contaminated infant formula and improper claims to federal and state programs.
Aug 25, 2026, 18:49 UTC
Abbott received FDA authorization for its Libre Duo 10 Day system, the world's first dual glucose-ketone sensing biowearable for people with diabetes.
Aug 20, 2026, 17:15 UTC
Medtronic's MiniMed Flex insulin pump system, paired with Abbott's 15-day Instinct sensor, is now shipping in the United States.
Source:
Page 1Next →